According to a report from planetofthevapes on August 31st, a team from the MUSC Hollings Cancer Center in the United States has conducted the largest-ever study on e-cigarettes, demonstrating their value as a tool for smoking cessation.
E-cigarettes contain harmful chemicals, which has led many public health advocates to avoid them. However, they are less harmful than traditional cigarettes, which can cause more than a dozen types of cancer, as well as heart disease, stroke, diabetes, and chronic obstructive pulmonary disease," said MUSC Hollings Cancer Center.
This new study, which is the largest e-cigarette trial in the United States, suggests that the use of e-cigarettes encourages people to quit smoking - even those who participated in the study and expressed no intention to quit smoking.
The team's research findings have been published in this month's eClinical Medicine journal, showing that those who received e-cigarette products exhibited higher cessation rates and less harm compared to those who did not receive e-cigarette products. However, the researchers also stated, "No one wants kids to have e-cigarettes, and we should do everything we can to prevent this from happening. But we shouldn't deny this option to adult smokers who are unable to quit.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
